For the millions of patients with atrial fibrillation, the left atrial appendage is a small, finger-like sac in the heart that poses an outsized risk. It's a primary site for blood clots that can travel to the brain, causing a devastating stroke. The current gold standard for high-risk patients who cannot tolerate blood thinners is a permanent metal implant, delivered via catheter to plug the appendage. A new University of Chicago spinout, however, is betting that a temporary scaffold and a biocompatible gel might offer a more tailored, and potentially gentler, alternative.
Parasol Med Tech is developing an investigational, patient-specific left atrial appendage (LAA) closure system. The integrated catheter-and-gel approach is designed to conform to a patient's unique cardiac anatomy, with the goal of reducing the long-term presence of a rigid metal device [Polsky Center, October 2026]. Founded by interventional cardiologist Dr. Atman Shah, the company has secured $3 million in pre-seed funding to advance the technology from prototype through preclinical testing [Polsky Center, October 2026].
The Anatomy-Driven Wedge
The clinical premise is straightforward: no two hearts are identical. The LAA's size, shape, and orientation vary significantly from patient to patient. Existing occluder devices, while effective, are off-the-shelf implants that must be sized to fit within a range of anatomies. Parasol's proposed system seeks to move beyond a one-size-fits-most model. Its differentiation lies in an anatomy-driven closure approach that combines temporary structural control with the delivery of a gel material [Polsky Center, October 2026]. The concept is to use a catheter to deploy a temporary scaffold that shapes the gel as it solidifies, creating a custom-fit seal. This method aims to address clot formation at its source while potentially mitigating complications associated with permanent metal, such as device-related thrombus or erosion.
A Team Built for the Clinic
The company's foundation is deeply clinical. Founder and Chief Medical Officer Atman Shah is a professor of medicine and clinical director of cardiology at the University of Chicago Medicine, with a specialization in minimally invasive, catheter-based interventions [Polsky Center, June 2026]. This places the technology's development squarely within the workflow and challenges of a practicing interventionalist. Evan Singer joined as CEO in mid-2026 to lead business strategy and operations [Polsky Center, June 2026]. The backing reflects a blend of academic and specialized medical venture capital, suggesting confidence in the technical and clinical roadmap.
| Investor | Type | Notable Detail |
|---|---|---|
| Cardiovascular Innovation Ventures | Corporate Venture | The American College of Cardiology's investment arm [Polsky Center, October 2026] |
| UCM Ventures | Hospital Venture | University of Chicago Medical Center's investment vehicle [Polsky Center, October 2026] |
| Harper Court Ventures | Venture Firm | Chicago-based early-stage investor [Polsky Center, October 2026] |
| George Shultz Innovation Fund | University Fund | University of Chicago fund that provided an initial $250,000 award [Polsky Center, June 2026] |
The Long Road to the Cath Lab
The ambition is significant, but the path is long and meticulously regulated. The system is investigational, meaning it has not been reviewed or approved by the FDA for commercial use. The $3 million in pre-seed capital is earmarked for prototype development, preclinical testing, and data generation for future regulatory and clinical milestones [Polsky Center, June 2026]. This early funding is a vote of confidence, but it is merely the first step in a capital-intensive journey that will require substantial Series A funding to support first-in-human trials and, eventually, pivotal studies for FDA clearance.
The competitive and clinical landscape presents a high bar. The market for LAA closure is dominated by established players with devices that have years of clinical data and commercial scale. For Parasol to gain traction, it must not only prove safety and efficacy but also demonstrate a meaningful clinical advantage,such as superior sealing, reduced complication rates, or applicability in complex anatomies,that justifies adoption by electrophysiologists and structural heart teams. The company's early differentiation on paper must withstand the rigorous scrutiny of animal studies and, later, human trials.
The Patient Population in Focus
The target is patients with non-valvular atrial fibrillation who are at increased risk of stroke and have a contraindication to long-term oral anticoagulation therapy. For these individuals, the standard of care today involves a transcatheter procedure where an interventional cardiologist guides a metal mesh occluder through the vasculature to the heart, deploying it to seal off the LAA. The procedure is effective but comes with a lifelong implant and associated monitoring. Parasol's bet is that a patient-conforming, gel-based closure could represent a next step in the evolution of this life-saving intervention, moving from a manufactured device to a personalized, biology-friendly barrier. The next twelve months will be critical for translating the concept into compelling preclinical data that can attract the deeper funding needed for the clinical phase.
Sources
- [Polsky Center, October 2026] Founded by UChicago Cardiologist, Parasol Secures $2.75M for Novel Medical Device to Improve Stroke Prevention | https://polsky.uchicago.edu/2026/10/26/founded-by-uchicago-cardiologist-parasol-secures-2-75m-for-novel-medical-device-to-improve-stroke-prevention/
- [Polsky Center, June 2026] George Shultz Innovation Fund Awards $250K to Parasol Medtech and Signl | https://polsky.uchicago.edu/2026/06/17/george-shultz-innovation-fund-awards-250k-to-parasol-medtech-and-signl/
- [Cardiac & Vascular News/CFR Journal, October 2026] Parasol Med Tech Secures $2.75M to Improve Stroke Prevention in Atrial Fibrillation
- [Chicago Business Journal, October 2026] UChicago spinout raises $2.75M for medical device to prevent strokes | https://www.bizjournals.com/chicago/news/2026/10/28/parasol-med-tech-afib-heart-device.html